Gopalakrishnan M, Johnson D E, Janis R A, Triggle D J
Department of Biochemical Pharmacology, School of Pharmacy, State University of New York, Buffalo.
J Pharmacol Exp Ther. 1991 Jun;257(3):1162-71.
Binding of the hypoglycemic sulfonylurea, [3H]glyburide, to crude membrane fractions from brain, heart and smooth (intestinal) muscle was saturable, linear with protein concentration and reversible. Saturation analysis revealed high affinity sites (KH values, 7 x 10(-11) M, 5 x 10(-11) M and 6 x 10(-11) M), with Bmax-H values 209, 36 and 23 fmol/mg protein in the brain, heart and smooth muscle, respectively. High affinity [3H]glyburide binding was pharmacologically specific, insensitive to a variety of receptor-active ligands, but sensitive to a series of sulfonylureas, and good, essentially 1:1, correlations were obtained between binding affinities and literature-derived pharmacologic activities. The K+ channel activators, cromakalim, nicorandil, pinacidil and minoxidil were not effective as inhibitors of [3H]glyburide binding. However, diazoxide was a modestly effective inhibitor. Putative low affinity sites (KL values, 3 x 10(-7) M, 1 x 10(-7) M and 2 x 10(-9) M) with Bmax-L values 4956, 336 and 53 fmol/mg protein in brain, heart and smooth muscle, respectively, were identified. Their significance remains to be established. Except for ATP gamma S, the ability of nucleotide triphosphates to inhibit high affinity [3H] glyburide binding was dependent on the presence of Mg++. ADP, in the presence of Mg++, inhibited binding with an IC50 value of 6.3 x 10(-4) M. Nucleotide monophosphates did not inhibit [3H] glyburide binding in the presence or absence of Mg++, whereas in the presence of Mg++, nucleotide triphosphates were equally potent inhibitors of binding. The rank order potency for nucleotide diphosphate inhibition of binding, in the presence of Mg++, is ADP greater than GDP greater than IDP = UDP. In the absence of Mg++, [3H]glyburide binding shows a biphasic response to ADP, and the inhibition of binding by ADP was prevented by ATP. It is suggested that this biphasic response is the result of a second nucleotide binding site.
降血糖磺脲类药物[3H]格列本脲与脑、心脏和平滑(肠)肌的粗膜组分的结合具有饱和性,与蛋白质浓度呈线性关系且可逆。饱和分析显示存在高亲和力位点(KH值分别为7×10^(-11)M、5×10^(-11)M和6×10^(-11)M),在脑、心脏和平滑肌中,Bmax-H值分别为209、36和23 fmol/mg蛋白质。高亲和力的[3H]格列本脲结合具有药理学特异性,对多种受体活性配体不敏感,但对一系列磺脲类药物敏感,并且结合亲和力与文献报道的药理活性之间存在良好的、基本为1:1的相关性。钾通道激活剂色满卡林、尼可地尔、匹那地尔和米诺地尔作为[3H]格列本脲结合的抑制剂无效。然而,二氮嗪是一种中等有效的抑制剂。在脑、心脏和平滑肌中分别鉴定出推定的低亲和力位点(KL值分别为3×10^(-7)M、1×10^(-7)M和2×10^(-9)M),其Bmax-L值分别为4956、336和53 fmol/mg蛋白质。它们的意义尚待确定。除了ATPγS外,三磷酸核苷酸抑制高亲和力[3H]格列本脲结合的能力取决于Mg++的存在。在Mg++存在下,ADP以6.3×10^(-4)M的IC50值抑制结合。在有或没有Mg++的情况下,单磷酸核苷酸均不抑制[3H]格列本脲结合,而在Mg++存在下,三磷酸核苷酸是同等有效的结合抑制剂。在Mg++存在下,二磷酸核苷酸抑制结合的效力顺序为ADP>GDP>IDP = UDP。在没有Mg++的情况下,[3H]格列本脲结合对ADP呈现双相反应,并且ATP可阻止ADP对结合的抑制作用。提示这种双相反应是第二个核苷酸结合位点的结果。